Bacterial imaging in tumour diagnosis DOI Creative Commons
Jian Chu, Yu Xiang, Gaofei Jiang

et al.

Microbial Biotechnology, Journal Year: 2024, Volume and Issue: 17(6)

Published: May 29, 2024

Some bacteria, such as Escherichia coli (E. coli) and Salmonella typhimurium (S. typhimurium), have an inherent ability to locate solid tumours, making them a versatile platform that can be combined with other tools improve the tumour diagnosis treatment. In anti-cancer therapy, bacteria function by carrying drugs directly or expressing exogenous therapeutic genes. The application of bacterial imaging in diagnosis, novel promising research area, indeed provide dynamic real-time monitoring both pre-treatment assessment post-treatment detection. Different techniques, including optical technology, acoustic imaging, magnetic resonance (MRI) nuclear medicine allow us observe track tumour-associated bacteria. Optical bioluminescence fluorescence, provides high-sensitivity high-resolution imaging. Acoustic is non-invasive technique good penetration depth spatial resolution. MRI high resolution radiation-free Nuclear positron emission tomography (PET) single photon computed (SPECT) information on distribution dynamics population. Moreover, strategies synthetic biology modification nanomaterial engineering viability localization while maintaining their autonomy vitality, thus aiding visualization gut However, there are some challenges, relatively low abundance heterogeneously within tumour, dimensionality datasets limitations labeling tools. summary, continuous development technology nanotechnology, it expected further make in-depth study develop new methods for diagnosis.

Language: Английский

Molecular and functional imaging in cancer-targeted therapy: current applications and future directions DOI Creative Commons
Jing‐Wen Bai, Si-Qi Qiu, Guo‐Jun Zhang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2023, Volume and Issue: 8(1)

Published: Feb. 27, 2023

Targeted anticancer drugs block cancer cell growth by interfering with specific signaling pathways vital to carcinogenesis and tumor rather than harming all rapidly dividing cells as in cytotoxic chemotherapy. The Response Evaluation Criteria Solid Tumor (RECIST) system has been used assess response therapy via changes the size of target lesions measured calipers, conventional anatomically based imaging modalities such computed tomography (CT), magnetic resonance (MRI), other methods. However, RECIST is sometimes inaccurate assessing efficacy targeted because poor correlation between treatment-induced necrosis or shrinkage. This approach might also result delayed identification when does confer a reduction size. Innovative molecular techniques have gained importance dawning era they can visualize, characterize, quantify biological processes at cellular, subcellular, even level anatomical level. review summarizes different pathways, various techniques, developed probes. Moreover, application for evaluating treatment related clinical outcome systematically outlined. In future, more attention should be paid promoting translation sensitivity biocompatible particular, multimodal technologies incorporating advanced artificial intelligence comprehensively accurately cancer-targeted therapy, addition RECIST-based

Language: Английский

Citations

93
Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation DOI Creative Commons
Shivang Dhoundiyal, Shriyansh Srivastava,

Sachin Kumar

et al.

European journal of medical research, Journal Year: 2024, Volume and Issue: 29(1)

Published: Jan. 5, 2024

This review article explores the dynamic field of radiopharmaceuticals, where innovative developments arise from combining radioisotopes and pharmaceuticals, opening up exciting therapeutic possibilities. The in-depth exploration covers targeted drug delivery, delving into passive targeting through enhanced permeability retention, as well active using ligand-receptor strategies. also discusses stimulus-responsive release systems, which orchestrate controlled release, enhancing precision effectiveness. A significant focus is placed on crucial role radiopharmaceuticals in medical imaging theranostics, highlighting their contribution to diagnostic accuracy image-guided curative interventions. emphasizes safety considerations strategies for mitigating side effects, providing valuable insights addressing challenges achieving precise delivery. Looking ahead, nanoparticle formulations cutting-edge innovations next-generation showcasing potential applications. Real-world examples are presented case studies, including use radiolabelled antibodies solid tumors, peptide receptor radionuclide therapy neuroendocrine intricate management bone metastases. concluding perspective envisions future trajectory anticipating a harmonious integration medicine artificial intelligence. vision foresees an era aligns seamlessly with scientific advancements, ushering new epoch marked by fusion resonance visionary progress.

Language: Английский

Citations

48
The Role of Small Molecules Containing Fluorine Atoms in Medicine and Imaging Applications DOI Creative Commons

Emily Henary,

Stefanie Casa, Tyler L. Dost

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(3), P. 281 - 281

Published: Feb. 22, 2024

The fluorine atom possesses many intrinsic properties that can be beneficial when incorporated into small molecules. These include the atom’s size, electronegativity, and ability to block metabolic oxidation sites. Substituents feature fluorine-containing groups are currently prevalent in drugs lower cholesterol, relieve asthma, treat anxiety disorders, as well improve chemical of various medications imaging agents. dye scaffolds (fluorescein/rhodamine, coumarin, BODIPY, carbocyanine, squaraine dyes) reported will address incorporation scaffold contribution it provides its application an agent. It is also important recognize radiolabeled atoms used for PET early detection diseases. This review discuss benefits incorporating molecules give examples fluorinated pharmaceutical industry techniques.

Language: Английский

Citations

20
Pathogenesis, Diagnostics, and Therapeutics for Alzheimer's Disease: Breaking the Memory Barrier DOI Creative Commons

Pushpa Tryphena Kamatham,

Rashi K. Shukla, Dharmendra Kumar Khatri

et al.

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 101, P. 102481 - 102481

Published: Sept. 3, 2024

Alzheimer's disease (AD) is the most common cause of dementia and accounts for 60-70 % all cases. It affects millions people worldwide. AD poses a substantial economic burden on societies healthcare systems. progressive neurodegenerative disorder characterized by cognitive decline, memory loss, impaired daily functioning. As prevalence continues to increase, understanding its pathogenesis, improving diagnostic methods, developing effective therapeutics have become paramount. This comprehensive review delves into intricate mechanisms underlying AD, explores current state techniques, examines emerging therapeutic strategies. By revealing complexities this aims contribute growing body knowledge surrounding devastating disease.

Language: Английский

Citations

18
Small-molecule probes from bench to bedside: advancing molecular analysis of drug–target interactions toward precision medicine DOI
Sijun Pan, Aixiang Ding, Yisi Li

et al.

Chemical Society Reviews, Journal Year: 2023, Volume and Issue: 52(16), P. 5706 - 5743

Published: Jan. 1, 2023

Integrated development of designer chemical tools and complementary analytical technologies empowers new scientific clinical opportunities.

Language: Английский

Citations

31
Skin Cancer Pathobiology at a Glance: A Focus on Imaging Techniques and Their Potential for Improved Diagnosis and Surveillance in Clinical Cohorts DOI Open Access
Elena-Georgiana Dobre, Mihaela Surcel, Carolina Constantin

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(2), P. 1079 - 1079

Published: Jan. 5, 2023

Early diagnosis is essential for completely eradicating skin cancer and maximizing patients' clinical benefits. Emerging optical imaging modalities such as reflectance confocal microscopy (RCM), coherence tomography (OCT), magnetic resonance (MRI), near-infrared (NIR) bioimaging, positron emission (PET), their combinations provide non-invasive data that may help in the early detection of cutaneous tumors surgical planning. Hence, they seem appropriate observing dynamic processes blood flow, immune cell activation, tumor energy metabolism, which be relevant disease evolution. This review discusses latest technological methodological advances techniques applied monitoring. In first instance, we will describe principle prospective applications most commonly used techniques, highlighting challenges opportunities implementation setting. We also highlight how complement molecular histological approaches sharpening characterization, laying ground more personalized patients.

Language: Английский

Citations

26
Molecular Imaging Diagnosis of Renal Cancer Using 99mTc-Sestamibi SPECT/CT and Girentuximab PET-CT-Current Evidence and Future Development of Novel Techniques DOI Creative Commons
Octavian Sabin Tătaru, Michele Marchioni, Felice Crocetto

et al.

Diagnostics, Journal Year: 2023, Volume and Issue: 13(4), P. 593 - 593

Published: Feb. 6, 2023

Novel molecular imaging opportunities to preoperatively diagnose renal cell carcinoma is under development and will add more value in limiting the postoperative function loss morbidity. We aimed comprehensively review research on single photon emission computed tomography/computed tomography (SPECT/CT) positron (PET-CT) enhance urologists’ radiologists’ knowledge of current pattern. identified an increase prospective also retrospective studies that researched distinguish between benign malignant lesions different clear subtypes, with small numbers patients studied, nonetheless excellent results specificity, sensitivity accuracy, especially for 99mTc-sestamibi SPECT/CT delivers quick compared a long acquisition time girentuximab PET-CT, which instead gives better image quality. Nuclear medicine has helped clinicians evaluating primary secondary lesions, lately returned new exciting insights novel radiotracers reinforce its diagnostic potential carcinoma. To further limit post-surgery morbidity, future mandatory validate clinically implement techniques context precision medicine.

Language: Английский

Citations

24
Recent Advances in 64Cu/67Cu-Based Radiopharmaceuticals DOI Open Access
Olga O. Krasnovskaya,

Daniil Abramchuck,

Alexander S. Erofeev

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(11), P. 9154 - 9154

Published: May 23, 2023

Copper-64 (T1/2 = 12.7 h) is a positron and beta-emitting isotope, with decay characteristics suitable for both emission tomography (PET) imaging radiotherapy of cancer. Copper-67 61.8 beta gamma emitter, appropriate β-energy half-life single-photon computed (SPECT) imaging. The chemical identities 64Cu 67Cu isotopes allow convenient use the same chelating molecules sequential PET radiotherapy. A recent breakthrough in production opened previously unavailable opportunities reliable source high specific activity purity. These new have reignited interest copper-containing radiopharmaceuticals therapy, diagnosis, theranostics various diseases. Herein, we summarize (2018–2023) advances copper-based PET, SPECT imaging, radiotherapy, radioimmunotherapy.

Language: Английский

Citations

23
Role of Artificial Intelligence in Medical Image Analysis: A Review of Current Trends and Future Directions DOI
Xin Li, Lei Zhang, Jingsi Yang

et al.

Journal of Medical and Biological Engineering, Journal Year: 2024, Volume and Issue: 44(2), P. 231 - 243

Published: April 1, 2024

Language: Английский

Citations

12
Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy DOI Creative Commons

Nina Eißler,

Renske Altena, Ali Alhuseinalkhudhur

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(5), P. 1088 - 1088

Published: May 14, 2024

Human epidermal growth factor receptor 2 (HER2) is a major prognostic and predictive marker overexpressed in 15–20% of breast cancers. The diagnostic reference standard for selecting patients HER2-targeted therapy based on the analysis tumor biopsies. Previously were defined as HER2-positive or -negative; however, with approval novel treatment options, specifically antibody–drug conjugate trastuzumab deruxtecan, many cancer tumors expressing low levels HER2 have become eligible therapy. Such will need to be reliably identified by suitable methods. Biopsy-based diagnostics are invasive, repeat biopsies not always feasible. They cannot visualize heterogeneity expression, leading substantial number misdiagnosed patients. An alternative highly accurate method molecular imaging radiotracers. In case HER2, various studies demonstrate clinical utility feasibility such approaches. Radiotracers Affibody® molecules, small, engineered affinity proteins size ~6.5 kDa, clinically validated molecules favorable characteristics imaging. this article, we summarize therapeutic landscape, describe our experience review currently available data HER2-Affibody-based tool beyond.

Language: Английский

Citations

10